Focus

 

Call for applications - 2019 Executive Training on Drug Policy

Following the successful training sessions in the previous years, the Pompidou Group is happy to announce that it will organise the Executive Training on Drug Policy in 2019 on “Incorporating gender dimensions in drug policy practice and service delivery”.

A unique format of the training provides a rare opportunity for professionals working in the drug policy field to have a hands-on training in an international environment.

Given the high level of interest in the Pompidou Group’s Executive Trainings, the course is open to all Council of Europe member States and interested non-member States.

The working language of the training is English.

Profile of participants: The training course will be targeting managers from governmental/public institutions that are responsible for developing and/or implementing drug policies and/or coordinating related programme implementation, service delivery as well as the representatives from civil society organisations working in the various sectors and formats that are related to drug policies.

Those interested in applying for the training may contact the Permanent Correspondent of their country and ask for the participation form. In casy of any difficulties, please contact the Secretariat.

Deadline for submitting applications is 10 February 2019.

 

 

Video Video

twitter feed twitter feed
New publication New publication

"Opioid Agonist Treatment, Guiding Principles for Legislation and Regulations"

With nearly 35 million opioid users worldwide, access to opioid agonist treatment (OAT) is a major health issue. Only 12 million are intravenous drug users and are at risk of becoming infected with HIV or hepatitis C virus (HCV). These high-risk opioid users are close to 1.3 million in Europe. Only 50% have access to treatment and there are considerable differences from one country to another, between cities and rural territories, and in terms of population groups (women, minors, etc.). The major obstacle is the requirement to obtain prior approval, notwithstanding the effectiveness of this treatment which is beyond any doubt. Scaling up the access to opioid agonist medicines is a WHO recommendation and is part of the EU Action Plan on Drugs for 2017-2020. In particular, two medicines are deemed essential: methadone and buprenorphine. The report drafted by a group of health and legal experts thereby calls upon countries to review their national regulations in the light of four recommendations: (1) the delivery of opioid agonist medicines without prior approval; (2) the removal of financial barriers to health care access; (3) the setting up of a national consultative monitoring body; (4) the use of a neutral, precise and respectful terminology. All these courses of action are aimed at an equitable and timely access to health care, in alignment with the human rights-based approach recommended by the Pompidou Group.

 Pompidou Group